Liwei Jing1,2, Chao Zhang3, Wei Li4, Feng Jin5, Aiping Wang6. 1. National Academy of Development and Strategy, Renmin University of China, No. 59 Zhongguancun Street, Haidian District, Beijing, 100872, China. 2. College of Nursing and Rehabilitation, North China University of Science and Technology, No.21 Bohai Road, Caofeidian District, Tangshan, 063210, Hebei, China. 3. Affiliated Hospital of North China University of Science and Technology, Tangshan, 063210, Hebei, China. 4. Radiotherapy Department, Tangshan People's Hospital, No.65 Shengli Road, Lunan District, Tangshan, 063001, Hebei, China. 5. Breast Surgery, First Affiliated Hospital of China Medical University, Heping District, Nanjing street, No. 155, Shenyang, 110001, Liaoning, China. 6. Department of Nursing, First Affiliated Hospital of China Medical University, Heping District, Nanjing street, No. 155, Shenyang, 110001, Liaoning, China. jianghaoran88@hotmail.com.
Abstract
PURPOSE: Previous meta-analyses have examined the prevalence of sexual dysfunction among women with cancer, but there is no breast cancer (BC)-specific study. We therefore conducted a meta-analysis to examine the prevalence and severity of female sexual dysfunction (FSD) in women with BC. METHODS: We searched PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and VIP for relevant studies published between April 2000 and January 2017. Data were extracted from studies which assessed FSD prevalence and sexual function in women with BC using the female sexual function index (FSFI). Meta-analyses were performed by pooling the prevalence rates of FSD and total FSFI scores. Meta regression was performed to explore the sources of heterogeneity. RESULTS: We selected 19 published studies involving a total of 2684 women with BC. In this study population, overall FSD prevalence was 73.4% (95% confidence interval (CI) 64.0%, 82.8%), and the total FSFI score was 19.28 (95% CI 17.39, 21.16). Among Asian, American, and European women with BC, there were significant differences in FSD prevalence (P < 0.001), and there was marginally significant difference (P = 0.07) in sexual function between these groups. There was also a marginally significant difference between individuals from mainland China and from other countries in FSD prevalence (P = 0.06) and FSFI score (P = 0.07). CONCLUSIONS: Overall, women with BC have high FSD prevalence and low sexual function. American women with BC have a higher average FSD prevalence and lower average sexual function than Asian women with BC. The FSD prevalence in women with BC in mainland China was slightly higher than in other countries.
PURPOSE: Previous meta-analyses have examined the prevalence of sexual dysfunction among women with cancer, but there is no breast cancer (BC)-specific study. We therefore conducted a meta-analysis to examine the prevalence and severity of female sexual dysfunction (FSD) in women with BC. METHODS: We searched PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and VIP for relevant studies published between April 2000 and January 2017. Data were extracted from studies which assessed FSD prevalence and sexual function in women with BC using the female sexual function index (FSFI). Meta-analyses were performed by pooling the prevalence rates of FSD and total FSFI scores. Meta regression was performed to explore the sources of heterogeneity. RESULTS: We selected 19 published studies involving a total of 2684 women with BC. In this study population, overall FSD prevalence was 73.4% (95% confidence interval (CI) 64.0%, 82.8%), and the total FSFI score was 19.28 (95% CI 17.39, 21.16). Among Asian, American, and European women with BC, there were significant differences in FSD prevalence (P < 0.001), and there was marginally significant difference (P = 0.07) in sexual function between these groups. There was also a marginally significant difference between individuals from mainland China and from other countries in FSD prevalence (P = 0.06) and FSFI score (P = 0.07). CONCLUSIONS: Overall, women with BC have high FSD prevalence and low sexual function. American women with BC have a higher average FSD prevalence and lower average sexual function than Asian women with BC. The FSD prevalence in women with BC in mainland China was slightly higher than in other countries.
Entities:
Keywords:
Breast cancer; Female sexual dysfunction; Female sexual function index; Meta-analysis; Prevalence
Authors: F M Nimbi; S Magno; L Agostini; A Di Micco; C Maggiore; B M De Cesaris; R Rossi; R Galizia; C Simonelli; R Tambelli Journal: Breast Cancer Date: 2022-01-06 Impact factor: 3.307
Authors: Jessica R Gorman; Karen S Lyons; Jennifer Barsky Reese; Chiara Acquati; Ellie Smith; Julia H Drizin; John M Salsman; Lisa M Flexner; Brandon Hayes-Lattin; S Marie Harvey Journal: Front Psychol Date: 2022-02-04
Authors: Solveig K Smedsland; Kathrine F Vandraas; Synne K Bøhn; Alv A Dahl; Cecilie E Kiserud; Mette Brekke; Ragnhild S Falk; Kristin V Reinertsen Journal: Breast Cancer Res Treat Date: 2022-02-28 Impact factor: 4.872
Authors: Cynthia Villarreal-Garza; Alejandra Platas; Melina Miaja; Alan Fonseca; Fernanda Mesa-Chavez; Marisol Garcia-Garcia; Judy-Anne Chapman; Edna A Lopez-Martinez; Claudia Pineda; Alejandro Mohar; Carmen L Galvez-Hernandez; Andrea Castro-Sanchez; Bertha-Alejandra Martinez-Cannon; Regina Barragan-Carrillo; Jose F Muñoz-Lozano; Paul Goss; Juan E Bargallo-Rocha; Dione Aguilar; Servando Cardona; Mauricio Canavati Journal: JCO Glob Oncol Date: 2020-03